Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has been given a consensus rating of “Hold” by the nine analysts that are covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $69.80.
EGRX has been the topic of a number of research reports. BidaskClub downgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 7th. Royal Bank of Canada set a $66.00 target price on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, March 1st. Zacks Investment Research raised shares of Eagle Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $51.00 target price on the stock in a research note on Monday, December 17th. Finally, ValuEngine raised shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 1st.
NASDAQ:EGRX opened at $47.02 on Friday. The company has a current ratio of 4.13, a quick ratio of 3.92 and a debt-to-equity ratio of 0.24. The company has a market cap of $654.71 million, a price-to-earnings ratio of 22.50 and a beta of 1.73. Eagle Pharmaceuticals has a fifty-two week low of $36.03 and a fifty-two week high of $85.66.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its earnings results on Thursday, February 28th. The specialty pharmaceutical company reported $1.20 EPS for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.04. Eagle Pharmaceuticals had a net margin of 14.96% and a return on equity of 17.76%. The business had revenue of $56.05 million for the quarter, compared to the consensus estimate of $54.17 million. During the same quarter last year, the firm posted $1.05 EPS. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. On average, equities analysts predict that Eagle Pharmaceuticals will post 3.43 earnings per share for the current fiscal year.
In other news, CEO Scott Tarriff sold 31,569 shares of the firm’s stock in a transaction on Thursday, January 3rd. The shares were sold at an average price of $39.49, for a total value of $1,246,659.81. Following the transaction, the chief executive officer now owns 1,543,459 shares of the company’s stock, valued at approximately $60,951,195.91. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 86,082 shares of company stock worth $3,746,371. Insiders own 28.20% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its holdings in Eagle Pharmaceuticals by 21.6% during the 3rd quarter. BlackRock Inc. now owns 1,741,712 shares of the specialty pharmaceutical company’s stock valued at $120,753,000 after purchasing an additional 309,622 shares in the last quarter. Park West Asset Management LLC grew its holdings in Eagle Pharmaceuticals by 41.6% during the 4th quarter. Park West Asset Management LLC now owns 1,050,000 shares of the specialty pharmaceutical company’s stock valued at $42,304,000 after purchasing an additional 308,574 shares in the last quarter. Millennium Management LLC grew its holdings in Eagle Pharmaceuticals by 2,385.0% during the 4th quarter. Millennium Management LLC now owns 284,753 shares of the specialty pharmaceutical company’s stock valued at $11,473,000 after purchasing an additional 273,294 shares in the last quarter. Norges Bank acquired a new stake in Eagle Pharmaceuticals during the 4th quarter valued at $10,948,000. Finally, WINTON GROUP Ltd acquired a new stake in Eagle Pharmaceuticals during the 4th quarter valued at $9,552,000. 92.54% of the stock is currently owned by institutional investors and hedge funds.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Recommended Story: How do buyers and sellers choose a strike price?
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.